Rhythm Pharmaceuticals Inc — Cash Flow (NASDAQ:RYTM) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -121.98 M-146 M-173.43 M-136.16 M-113.88 M-115.67 M -115.67 M Cash from investing activities 158.53 M-62.16 M28.03 M-5.67 M-48.17 M-137.15 M -137.15 M Cash from financing activities 2.01 M166.48 M213.83 M74.37 M191.24 M217.96 M 217.96 M Free cash flow -122.19 M-146.44 M-173.71 M-141.87 M-154.38 M-156.63 M -115.67 M

News

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity - Slideshow (NASDAQ:RYTM) 2026-03-24

Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat

Needham cuts Rhythm Pharmaceuticals stock price target on trial miss

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial - Slideshow (NASDAQ:RYTM) 2026-03-17

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript

Rhythm Pharma shares fall as obesity drug trial fails to meet main goal

Stifel reiterates Rhythm Pharmaceuticals stock rating at buy

Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA (NASDAQ:RYTM)